The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 02, 2025

Filed:

Aug. 25, 2020
Applicant:

Remegen Co., Ltd., Shandong, CN;

Inventors:

Jianmin Fang, Shandong, CN;

Jing Jiang, Shandong, CN;

Shenjun Li, Shandong, CN;

Guorui Zhao, Shandong, CN;

Assignee:

REMEGEN CO., LTD., Shandong, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/63 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C12N 15/62 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2827 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 15/62 (2013.01); C12N 15/63 (2013.01); C12N 2510/00 (2013.01);
Abstract

Provided in the present invention is a PD-L1 immunosuppressant, and specifically provided are a monoclonal antibody capable of targeting PD-L1, and nucleotides, combinations of polynucleotides, expression vectors and combinations of expression vectors encoding the antibody. Also provided in the present invention is a conjugate or pharmaceutical composition containing the above-mentioned anti PD-L1 antibody. Further provided in the present invention is the use of the above-mentioned anti PD-L1 antibody, nucleotides, combinations of polynucleotides, expression vectors, combinations of expression vectors, conjugate or pharmaceutical composition in the preparation of a medicament for treating or preventing cancers.


Find Patent Forward Citations

Loading…